Psychiatric DisorderNCT07914192
Antipsychotic Safety and Adherence in Patients With Psychiatric Disorders-An Egyptian Institution-Based Cross-Sectional Study.
An observational study of Psychiatric Disorder, run by Egyptian Chinese University.
Trial summary
This study aims to understand the safety of antipsychotic medications and how consistently patients take these medicines in Egypt. It will involve adult patients aged 18-65 years who are receiving antipsychotic medications at participating psychiatric hospitals in Cairo. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Psychiatric Disorder
- How many people
- 250 participants
- Where
- No sites listed yet
- Study dates
- 20 Oct 2026to 1 Feb 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: adult patients aged 18-65 years, of either sex, who are receiving antipsychotic medications at the participating psychiatric institutions in Cairo, Egypt: Okasha Institute of Psychiatry, Ain Shams University Hospital; Abbasia Hospital for Mental Health; and Heliopolis Psychiatric Hospital (Al-Matar).
Who may be able to join
- Patients aged 18 to 65 years, of either gender, who are admitted to the participating institutions and are receiving antipsychotic medications.
- Adequate cognitive ability to understand and follow study procedures
Who cannot join
- Patients who don't have enough cognitive ability to complete the questionnaire
- Patients who refuse to provide written informed consent
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
This study aims to understand the safety of antipsychotic medications and how consistently patients take these medicines in Egypt. It will involve adult patients aged 18-65 years who are receiving antipsychotic medications at participating psychiatric hospitals in Cairo.
The study will assess the side effects experienced by patients, their medication-taking habits, and their quality of life. Information will be collected through questionnaires, medical records, clinical assessments, and available laboratory test results.
Read more
The study is observational, meaning that participants will continue to receive their usual medical care, and the researchers will not assign any new treatment or medication as part of the study. Data will be collected at one point in time, without planned follow-up visits for research purposes.
The findings may help healthcare professionals better understand the side effects of antipsychotic medications, identify factors associated with medication non-adherence, and improve patient counseling and treatment monitoring. Participation is voluntary, and eligible patients will be asked to provide written informed consent. Participants' privacy and confidentiality will be protected.
- Conditions
- Psychiatric Disorder
- Keywords
- Antipsychotics, Medication Adherence, Side effects, Cross Sectional
- Medical subject headings
- Mental Disorders, Medication Adherence
What is being measured
The primary outcome is the main question the study is designed to answer.
Safety profile and adverse effects associated with antipsychotics use
Assessment of the safety profile and adverse effects associated with antipsychotic medication use among participating patients.
Measured: At Baseline Day 1
Secondary outcomes (2)
Adherence to antipsychotic medication
Assessment of participants' adherence to antipsychotic medication.
Measured: At Baseline Day 1
Prevalence of antipsychotics non-adherence
Determination of the prevalence of non-adherence to antipsychotic medication among participating patients.
Measured: At Baseline Day 1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Nov 2026
- Study start20 Oct 2026 (estimated)
- Primary completion1 Jan 2027 (estimated)
- Study completion1 Feb 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Psychiatric DisorderStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 250 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Egyptian Chinese University
- Sponsor type
- University, hospital or other
- Collaborators
- Ain Shams University
- Responsible party
- Principal investigator, Sarah Sabry Hashem Nafea, Egyptian Chinese University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07914192
- Sponsor's protocol ID
- 1
- Status last verified
- Oct 2026
- First submitted
- 19 Oct 2026
- Last updated
- 3 Nov 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Data will be made available on request
Study at a glance
From the registry record, last updated by the sponsor on 3 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Antipsychotic Safety and Adherence in Patients With Psychiatric Disorders-An Egyptian Institution-Based Cross-Sectional Study.
- ClinicalTrials.gov ID
- NCT07914192
- Acronym / sponsor ID
- 1
- Conditions
- Psychiatric Disorder
- Keywords
- Antipsychotics, Medication Adherence, Side effects, Cross Sectional
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 250 participants (estimated)
- Lead sponsor
- Egyptian Chinese UniversityUniversity, hospital or other
- Collaborators
- Ain Shams University
- Study start
- 20 Oct 2026 (estimated)
- Primary completion
- 1 Jan 2027 (estimated)
- Study completion
- 1 Feb 2027 (estimated)
- First posted
- 3 Nov 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to understand the safety of antipsychotic medications and how consistently patients take these medicines in Egypt. It will involve adult patients aged 18-65 years who are receiving antipsychotic medications at participating psychiatric hospitals in Cairo.
The study will assess the side effects experienced by patients, their medication-taking habits, and their quality of life. Information will be collected through questionnaires, medical records, clinical assessments, and available laboratory test results.
The study is observational, meaning that participants will continue to receive their usual medical care, and the researchers will not assign any new treatment or medication as part of the study. Data will be collected at one point in time, without planned follow-up visits for research purposes.
The findings may help healthcare professionals better understand the side effects of antipsychotic medications, identify factors associated with medication non-adherence, and improve patient counseling and treatment monitoring. Participation is voluntary, and eligible patients will be asked to provide written informed consent. Participants' privacy and confidentiality will be protected.
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- adult patients aged 18-65 years, of either sex, who are receiving antipsychotic medications at the participating psychiatric institutions in Cairo, Egypt: Okasha Institute of Psychiatry, Ain Shams University Hospital; Abbasia Hospital for Mental Health; and Heliopolis Psychiatric Hospital (Al-Matar).
Key inclusion criteria (2 listed)
- Patients aged 18 to 65 years, of either gender, who are admitted to the participating institutions and are receiving antipsychotic medications.
- Adequate cognitive ability to understand and follow study procedures
Key exclusion criteria (2 listed)
- Patients who don't have enough cognitive ability to complete the questionnaire
- Patients who refuse to provide written informed consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Safety profile and adverse effects associated with antipsychotics use
Time frame: At Baseline Day 1
Assessment of the safety profile and adverse effects associated with antipsychotic medication use among participating patients.
2 secondary outcomes
Adherence to antipsychotic medication
Time frame: At Baseline Day 1
Prevalence of antipsychotics non-adherence
Time frame: At Baseline Day 1
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Nov 2026.
- Individual participant dataSharing planned: No. Data will be made available on request
Related trials for Psychiatric Disorder
Not yet recruiting
Effect of Stress Ball Use During Femoral Arterial Sheath Removal After Coronary Angiography
Femoral Arterial Sheath Removal, Stress Ball
RecruitingPhase 2
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Alzheimer's Disease
Enrolling by invitationPhase 3
An Open-Label Study to Assess the Long-Term Safety of Solriamfetol in Children and Adolescents With ADHD
ADHD
Recruiting
Unified Protocol in Penitentiary Facilities
Depression Disorders, Anxiety
Recruiting
Safety and Performance of UCon Patch Electrode
Urinary Incontinence, Urinary Incontinence, Urge
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
An observational study of Psychiatric Disorder, run by Egyptian Chinese University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 3 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Sawsan Aboul-Fotouh, MD (+201221250399, sawsanaf2005@yahoo.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Safety profile and adverse effects associated with antipsychotics use (time frame: At Baseline Day 1). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Nov 2026.